Tramadol use in pediatric sickle cell disease patients with vaso-occlusive crisis

doi:10.5409/wjcp.v2.i4.65

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5672)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

389

HTML

2960

Figures (1-1)

235

Tables (1-3)

284

Sum=3868

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1023

Download

781

Sum=1804

Nov 8, 2013 (publication date) through Sep 18, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Pediatrics

ISSN

2219-2808

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Clin Pediatr. Nov 8, 2013; 2(4): 65-69
Published online Nov 8, 2013. doi: 10.5409/wjcp.v2.i4.65

Table 1 Baseline characteristics

	Morphine	Morphine + tramadol
Sample size	18	12
Age (yr), Mean (range)	11.5 (3-20)	13.4 (7-20)
Gender
Male	9	6
Female	9	6
Weight (kg), mean (range)	38.7 (11.6-77.4)	52 (27.0-77.4)^a
Hemoglobin (mg/dL), mean (range)	9.0 (6.0- 11.9)	9.4 (6.5-12.0)

^aP < 0.05 vs morphine.

Citation: Borgerding MP, Absher RK, So TY. Tramadol use in pediatric sickle cell disease patients with vaso-occlusive crisis. World J Clin Pediatr 2013; 2(4): 65-69
URL: https://www.wjgnet.com/2219-2808/full/v2/i4/65.htm
DOI: https://dx.doi.org/10.5409/wjcp.v2.i4.65